How Changes in CT Scans Over a Year Predict Outcomes in Fibrotic Lung Disease
Recent advances in AI-enhanced CT scan analysis enable early prediction of disease progression and survival in patients with fibrotic lung diseases, potentially transforming patient management and treatment strategies.
Researchers at National Jewish Health have discovered that subtle increases in lung scarring, observed through CT scans taken one year apart, can serve as important indicators of disease progression and patient survival in those with fibrotic interstitial lung diseases. Utilizing an artificial intelligence-based tool known as deep learning data-driven textural analysis (DTA), scientists measured changes in lung fibrosis with high precision. These advancements reveal that even small increases in fibrosis scores are linked to accelerated decline in lung function and higher risks of death or lung transplantation.
The study highlights that patients experiencing a 5% or greater increase in fibrosis score had more than double the risk of mortality or needing a lung transplant within the following year. Interestingly, the most significant changes were observed in patients with less severe initial disease, emphasizing the potential of early intervention. Dr. Matthew Koslow, lead co-author, explained that these findings could transform how clinicians monitor disease progression by providing an objective, early warning system based on imaging data.
Traditionally, predicting the course of fibrotic interstitial lung diseases, such as idiopathic pulmonary fibrosis (IPF), relies on symptoms, lung function tests, and radiologist assessments—which can be subjective and inconsistent. The new approach employs advanced image analysis technology to quantify fibrosis, offering a more consistent and predictive measure.
The study was validated using data from the Pulmonary Fibrosis Foundation Patient Registry, supporting its broad applicability. Quantitative CT analysis not only enhances disease monitoring but also holds promise for improving clinical trial endpoints, patient selection, and treatment planning.
According to Dr. David Baraghoshi, this research illustrates how robust statistical models combined with imaging can reveal meaningful patterns in disease progression. Overall, these findings suggest that regular assessment of fibrosis via AI-driven CT analysis could significantly refine prognostication and management strategies for fibrotic lung diseases.
Source: https://medicalxpress.com/news/2025-10-ct-scan-year-outcomes-fibrotic.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Ozempic Demonstrates Superior Stroke Risk Reduction Compared to Other Diabetes Medications
Semaglutide, marketed as Ozempic, shows a slightly lower risk of stroke compared to empagliflozin in patients with type 2 diabetes, offering promising cardiovascular benefits.
Certain Vape Flavors May Enhance Nicotine Reward in Adolescent Mice
Research indicates that flavored e-cigarettes can enhance reward-seeking behaviors in adolescent mice, even without nicotine, highlighting potential addiction risks of flavored vaping products.
Alarming Rise of Type 2 Diabetes Among Young New Zealanders Sparks Health Concerns
New Zealand faces a health crisis with a rising number of young people developing type 2 diabetes. This early-onset form of the disease is linked to obesity, social inequality, and lifestyle factors, challenging health systems and requiring urgent, coordinated action.